Intelligencia AI

Intelligencia AI is listed as a New York City artificial intelligence company[1] operating in the enterprise AI sector[1]. The company uses artificial intelligence to de-risk drug development[2]. Its platform focuses on estimating the risk of clinical trials and interpreting the multitude of factors that contribute to that risk[2]. According to the company, it bridges the gap between innovation and risk reduction, with the goal of bringing novel therapies to patients faster[2]. The company's interdisciplinary team comprises software engineers, AI practitioners, scientists, and drug developers who combine and interpret disparate data across the life sciences[2]. As of available records, Intelligencia AI has 114 employees[3] and operates in the software development industry[3].

Something wrong or missing? Send a correction. Fixed within 24 hours.